This product offers a CRISPR/Cas9-edited polyclonal knockout cell population of BAG5 in the human colorectal carcinoma HCT 116 cell line. The polyclonal format comprises a heterogeneous mixture of cells with targeted disruption of BAG5, delivering a robust loss-of-function model without requiring single-cell cloning. It is designed for reliable interrogation of BAG5-dependent pathways in a cancer-relevant background.
HCT 116 is an extensively characterized colorectal epithelial cell line harboring a KRAS G13D mutation, microsatellite instability, and wild-type p53. This genetic makeup renders it a valuable platform for studying oncogenic signaling, stress responses, and protein homeostasis. The BAG5 knockout counterpart builds on this well-defined background, enabling precise dissection of co-chaperone functions in tumor cell biology.
BAG5 encodes a co-chaperone that inhibits Hsp70 ATPase activity and negatively regulates Parkin-mediated mitophagy by impairing Parkin ubiquitination. It also promotes ??-synuclein aggregation, linking it to neurodegenerative pathology. BAG5 is activated by cellular stress and proteasome inhibition, and it suppresses Hsp70 chaperone function, Parkin-dependent mitochondrial clearance, and apoptosis signaling. Molecular partners include Hsp70/Hsc70, ??-synuclein, Parkin, and CHIP, placing BAG5 at the crossroads of proteasomal and autophagic degradation pathways.
In HCT 116 cells, BAG5 knockout removes the inhibitory constraint on Hsp70 and Parkin, thereby enhancing protein quality control and mitophagy, and sensitizing cells to apoptosis. This shift provides insight into how colorectal cancer cells adapt to proteotoxic stress and offers a model to study the role of chaperone networks in tumor cell survival and therapy resistance.
Applications for these polyclonal knockout cells span colorectal cancer research, proteostasis and autophagy studies, and Parkinson??s disease modeling. They support western blotting, RT-qPCR, apoptosis and mitophagy assays, co-immunoprecipitation, and Hsp70 ATPase activity measurement. High-throughput screening for BAG5?CHsp70?CParkin pathway modulators is also feasible. For more information, please contact Ascent Research.
